Recent breakthroughs in the field of obesity treatment have presented a innovative candidate known as ALLUVI Retatrutide. This compound is a {highlyspecific GLP-1 receptor agonist, engineered to amplify the effects of natural glucagon-like peptide-1. Retatrutide has shown impressive results in clinical trials, highlighting significant decreases in